Owens & Minor, Inc. (NYSE:OMI) Receives $20.00 Consensus PT from Brokerages

Shares of Owens & Minor, Inc. (NYSE:OMI - Get Free Report) have received an average rating of "Hold" from the eight analysts that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $20.00.

A number of brokerages recently weighed in on OMI. Citigroup raised shares of Owens & Minor from a "neutral" rating to a "buy" rating and reduced their target price for the stock from $24.00 to $19.00 in a research note on Friday, July 19th. StockNews.com lowered shares of Owens & Minor from a "buy" rating to a "hold" rating in a research note on Monday, August 26th. Robert W. Baird reduced their price objective on shares of Owens & Minor from $20.00 to $19.00 and set a "neutral" rating for the company in a research note on Tuesday, July 16th. Barclays reduced their price objective on shares of Owens & Minor from $23.00 to $18.00 and set an "equal weight" rating for the company in a research note on Monday, August 5th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Owens & Minor from $22.00 to $18.00 and set an "underweight" rating on the stock in a report on Wednesday, August 21st.

Hedge Funds Weigh In On Owens & Minor

A number of hedge funds have recently bought and sold shares of OMI. Quarry LP raised its holdings in shares of Owens & Minor by 290.1% during the second quarter. Quarry LP now owns 2,099 shares of the company's stock valued at $28,000 after purchasing an additional 1,561 shares during the period. Innealta Capital LLC acquired a new position in shares of Owens & Minor during the second quarter valued at about $43,000. DekaBank Deutsche Girozentrale raised its holdings in shares of Owens & Minor by 76.6% during the second quarter. DekaBank Deutsche Girozentrale now owns 3,126 shares of the company's stock valued at $43,000 after purchasing an additional 1,356 shares during the period. Blue Trust Inc. raised its holdings in shares of Owens & Minor by 176.8% during the third quarter. Blue Trust Inc. now owns 2,787 shares of the company's stock valued at $44,000 after purchasing an additional 1,780 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its holdings in shares of Owens & Minor by 100.6% during the second quarter. Allspring Global Investments Holdings LLC now owns 6,071 shares of the company's stock valued at $82,000 after purchasing an additional 3,044 shares during the period. Institutional investors own 98.04% of the company's stock.

Owens & Minor Trading Up 5.1 %

OMI stock traded up $0.65 during trading on Friday, hitting $13.36. The company had a trading volume of 1,527,146 shares, compared to its average volume of 826,687. The company has a quick ratio of 0.51, a current ratio of 1.09 and a debt-to-equity ratio of 2.17. The firm has a 50-day moving average price of $14.62 and a 200-day moving average price of $16.39. Owens & Minor has a 12 month low of $12.36 and a 12 month high of $28.35. The stock has a market cap of $1.03 billion, a price-to-earnings ratio of -23.86, a PEG ratio of 0.42 and a beta of 0.39.

Owens & Minor (NYSE:OMI - Get Free Report) last released its quarterly earnings data on Friday, August 2nd. The company reported $0.36 EPS for the quarter, beating analysts' consensus estimates of $0.33 by $0.03. Owens & Minor had a negative net margin of 0.40% and a positive return on equity of 14.66%. The business had revenue of $2.67 billion during the quarter, compared to analysts' expectations of $2.65 billion. During the same quarter in the prior year, the company earned $0.18 EPS. The firm's quarterly revenue was up 4.2% on a year-over-year basis. As a group, analysts predict that Owens & Minor will post 1.57 earnings per share for the current year.

Owens & Minor Company Profile

Owens & Minor, Inc, together with its subsidiaries, operates as a healthcare solutions company worldwide. It operates through Products & Healthcare Services and Patient Direct segments. The Products & Healthcare Services segment offers a portfolio of products and services to healthcare providers and manufacturers.